Caribou Biosciences up on FDA nod for cancer therapy
21/11/2022 16:59
** Drug developer Caribou Biosciences Inc's shares CRBU.O
rise 1.2% to $9.2
** Co says it received U.S. FDA clearance for its
Investigational New Drug application, enabling it to initiate a
clinical trial for CAR (chimeric antigen receptor) T-cell
therapy CB-011
** CRBU is developing CB-011 to treat relapsed or refractory
multiple myeloma, a form of cancer
** Co expects patient enrollment in CB-011's early-stage
safety and efficacy trial in early 2023
** The treatment is made of T-cells, which are white blood
cells that have been genetically altered to make them better
able to spot and attack cancer
** Including session moves, stock is down 39% YTD
(Reporting by Pratik Jain)
((Pratik.Jain@thomsonreuters.com;))